$122.96
-7.38-5.66%
Last update: Nov 6, 8:02 AM
Halozyme Therapeutics Inc
HALONASDAQ
The average analyst price target for Halozyme Therapeutics is $85.88, 27.2% below the current price. Of 10 analysts, 7 rate it Buy and 3 Hold. Targets range from $47 to $130. The latest change came on Nov 3, 2026, when JP Morgan raised its price target on Halozyme Therapeutics from $78 to $79 and kept a Neutral rating.
Price Target Range — 13 Quarters
Analyst Consensus — 10 Analysts
Rating Trend — Last 9 Months
